Vap is dead, page-7

Disappointing the rhinovirus trialed, but it did reduce viral load. Maybe they will proceed with the planned immunocomprimised trial as there is a different set of circumstances. The rhinovirus trial still saw similar symptoms in the control group, but much of the symptoms froma cold come from the immune system reacting (often over reacting leading to too much congestion). In immuncomprimised patients maybe the end result might be beneficial as the viral load could go down preventing significant disease with a different symptom profile due to their immunne system being unable to fire up to the same degree?